접합백신 : 세계 시장 점유율과 순위, 총판매량 및 수요 예측(2025-2031년)

The global market for Conjugate Vaccine was estimated to be worth US$ 10640 million in 2024 and is forecast to a readjusted size of US$ 13224 million by 2031 with a CAGR of 3.2% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Conjugate Vaccine cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Vaccines are used to prevent diseases by invoking an immune response to an antigen, the foreign part of a bacteria or virus that the immune system recognizes. Conjugate vaccines combine a weak antigen with a strong antigen as a carrier so that the immune system has a stronger response to the weak antigen.

The conjugate vaccine market is experiencing significant growth, primarily driven by the increasing global focus on preventing infectious diseases, especially among infants, children, and the elderly. Conjugate vaccines, which link a weak antigen to a strong carrier protein to enhance immune response, have proven highly effective against diseases like Haemophilus influenzae type b (Hib), pneumococcal, and meningococcal infections. Government immunization programs and public health initiatives-particularly in emerging economies-are expanding vaccine coverage, thereby fueling market demand. Additionally, rising investments from global health organizations (such as GAVI, WHO, and UNICEF), along with growing awareness of the importance of early immunization, are further boosting uptake. Technological advancements in vaccine development, including improved conjugation methods and novel carrier proteins, are enabling the production of more effective and broad-spectrum vaccines, supporting innovation and market expansion.

However, the conjugate vaccine market also faces notable challenges. High development and production costs, particularly for multivalent vaccines, can limit affordability and access in low-income regions. Stringent regulatory requirements and lengthy clinical trial timelines can delay product approvals, creating barriers for new entrants and smaller biotech firms. Cold chain logistics and storage requirements pose additional challenges in remote or underdeveloped areas, potentially impacting vaccine distribution and efficacy. Vaccine hesitancy, fueled by misinformation and lack of public trust in immunization programs, also poses a growing risk to market growth. Moreover, competition from alternative vaccine technologies, such as mRNA or protein subunit vaccines, may shift focus away from conjugate platforms in the long term. Addressing these challenges will require international collaboration to improve supply chains, expand funding for research and public health infrastructure, and enhance community education on vaccine safety and effectiveness.

This report aims to provide a comprehensive presentation of the global market for Conjugate Vaccine, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Conjugate Vaccine by region & country, by Type, and by End Users.

The Conjugate Vaccine market size, estimations, and forecasts are provided in terms of sales volume (Million Unit) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Conjugate Vaccine.

Market Segmentation

By Company

• Pfizer
• GSK
• Sanofi
• Merck
• Walvax Biotechnology
• Royal (Wuxi) Bio-Pharmaceutical
• Bharat Biotech
• Zhifei Biologic
• Beijing Minhai Biotechnology
• SinoPharma

Segment by Type

• Hib Vaccine
• Meningococcal Vaccine
• Pneumococcal Vaccine
• Others

Segment by End Users

• Children
• Adult

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Conjugate Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by End Users, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Conjugate Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Conjugate Vaccine in country level. It provides sigmate data by Type, and by End Users for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Conjugate Vaccine Product Introduction
• 1.2 Global Conjugate Vaccine Market Size Forecast
  • 1.2.1 Global Conjugate Vaccine Sales Value (2020-2031)
  • 1.2.2 Global Conjugate Vaccine Sales Volume (2020-2031)
  • 1.2.3 Global Conjugate Vaccine Sales Price (2020-2031)
• 1.3 Conjugate Vaccine Market Trends & Drivers
  • 1.3.1 Conjugate Vaccine Industry Trends
  • 1.3.2 Conjugate Vaccine Market Drivers & Opportunity
  • 1.3.3 Conjugate Vaccine Market Challenges
  • 1.3.4 Conjugate Vaccine Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Conjugate Vaccine Players Revenue Ranking (2024)
• 2.2 Global Conjugate Vaccine Revenue by Company (2020-2025)
• 2.3 Global Conjugate Vaccine Players Sales Volume Ranking (2024)
• 2.4 Global Conjugate Vaccine Sales Volume by Company Players (2020-2025)
• 2.5 Global Conjugate Vaccine Average Price by Company (2020-2025)
• 2.6 Key Manufacturers Conjugate Vaccine Manufacturing Base and Headquarters
• 2.7 Key Manufacturers Conjugate Vaccine Product Offered
• 2.8 Key Manufacturers Time to Begin Mass Production of Conjugate Vaccine
• 2.9 Conjugate Vaccine Market Competitive Analysis
  • 2.9.1 Conjugate Vaccine Market Concentration Rate (2020-2025)
  • 2.9.2 Global 5 and 10 Largest Manufacturers by Conjugate Vaccine Revenue in 2024
  • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Conjugate Vaccine as of 2024)
• 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 Hib Vaccine
  • 3.1.2 Meningococcal Vaccine
  • 3.1.3 Pneumococcal Vaccine
  • 3.1.4 Others
• 3.2 Global Conjugate Vaccine Sales Value by Type
  • 3.2.1 Global Conjugate Vaccine Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Conjugate Vaccine Sales Value, by Type (2020-2031)
  • 3.2.3 Global Conjugate Vaccine Sales Value, by Type (%) (2020-2031)
• 3.3 Global Conjugate Vaccine Sales Volume by Type
  • 3.3.1 Global Conjugate Vaccine Sales Volume by Type (2020 VS 2024 VS 2031)
  • 3.3.2 Global Conjugate Vaccine Sales Volume, by Type (2020-2031)
  • 3.3.3 Global Conjugate Vaccine Sales Volume, by Type (%) (2020-2031)
• 3.4 Global Conjugate Vaccine Average Price by Type (2020-2031)

4 Segmentation by End Users

• 4.1 Introduction by End Users
  • 4.1.1 Children
  • 4.1.2 Adult
• 4.2 Global Conjugate Vaccine Sales Value by End Users
  • 4.2.1 Global Conjugate Vaccine Sales Value by End Users (2020 VS 2024 VS 2031)
  • 4.2.2 Global Conjugate Vaccine Sales Value, by End Users (2020-2031)
  • 4.2.3 Global Conjugate Vaccine Sales Value, by End Users (%) (2020-2031)
• 4.3 Global Conjugate Vaccine Sales Volume by End Users
  • 4.3.1 Global Conjugate Vaccine Sales Volume by End Users (2020 VS 2024 VS 2031)
  • 4.3.2 Global Conjugate Vaccine Sales Volume, by End Users (2020-2031)
  • 4.3.3 Global Conjugate Vaccine Sales Volume, by End Users (%) (2020-2031)
• 4.4 Global Conjugate Vaccine Average Price by End Users (2020-2031)

5 Segmentation by Region

• 5.1 Global Conjugate Vaccine Sales Value by Region
  • 5.1.1 Global Conjugate Vaccine Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Conjugate Vaccine Sales Value by Region (2020-2025)
  • 5.1.3 Global Conjugate Vaccine Sales Value by Region (2026-2031)
  • 5.1.4 Global Conjugate Vaccine Sales Value by Region (%), (2020-2031)
• 5.2 Global Conjugate Vaccine Sales Volume by Region
  • 5.2.1 Global Conjugate Vaccine Sales Volume by Region: 2020 VS 2024 VS 2031
  • 5.2.2 Global Conjugate Vaccine Sales Volume by Region (2020-2025)
  • 5.2.3 Global Conjugate Vaccine Sales Volume by Region (2026-2031)
  • 5.2.4 Global Conjugate Vaccine Sales Volume by Region (%), (2020-2031)
• 5.3 Global Conjugate Vaccine Average Price by Region (2020-2031)
• 5.4 North America
  • 5.4.1 North America Conjugate Vaccine Sales Value, 2020-2031
  • 5.4.2 North America Conjugate Vaccine Sales Value by Country (%), 2024 VS 2031
• 5.5 Europe
  • 5.5.1 Europe Conjugate Vaccine Sales Value, 2020-2031
  • 5.5.2 Europe Conjugate Vaccine Sales Value by Country (%), 2024 VS 2031
• 5.6 Asia Pacific
  • 5.6.1 Asia Pacific Conjugate Vaccine Sales Value, 2020-2031
  • 5.6.2 Asia Pacific Conjugate Vaccine Sales Value by Region (%), 2024 VS 2031
• 5.7 South America
  • 5.7.1 South America Conjugate Vaccine Sales Value, 2020-2031
  • 5.7.2 South America Conjugate Vaccine Sales Value by Country (%), 2024 VS 2031
• 5.8 Middle East & Africa
  • 5.8.1 Middle East & Africa Conjugate Vaccine Sales Value, 2020-2031
  • 5.8.2 Middle East & Africa Conjugate Vaccine Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Conjugate Vaccine Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Conjugate Vaccine Sales Value and Sales Volume
  • 6.2.1 Key Countries/Regions Conjugate Vaccine Sales Value, 2020-2031
  • 6.2.2 Key Countries/Regions Conjugate Vaccine Sales Volume, 2020-2031
• 6.3 United States
  • 6.3.1 United States Conjugate Vaccine Sales Value, 2020-2031
  • 6.3.2 United States Conjugate Vaccine Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Conjugate Vaccine Sales Value by End Users, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Conjugate Vaccine Sales Value, 2020-2031
  • 6.4.2 Europe Conjugate Vaccine Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Conjugate Vaccine Sales Value by End Users, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Conjugate Vaccine Sales Value, 2020-2031
  • 6.5.2 China Conjugate Vaccine Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Conjugate Vaccine Sales Value by End Users, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Conjugate Vaccine Sales Value, 2020-2031
  • 6.6.2 Japan Conjugate Vaccine Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Conjugate Vaccine Sales Value by End Users, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Conjugate Vaccine Sales Value, 2020-2031
  • 6.7.2 South Korea Conjugate Vaccine Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Conjugate Vaccine Sales Value by End Users, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Conjugate Vaccine Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Conjugate Vaccine Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Conjugate Vaccine Sales Value by End Users, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Conjugate Vaccine Sales Value, 2020-2031
  • 6.9.2 India Conjugate Vaccine Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Conjugate Vaccine Sales Value by End Users, 2024 VS 2031

7 Company Profiles

• 7.1 Pfizer
  • 7.1.1 Pfizer Company Information
  • 7.1.2 Pfizer Introduction and Business Overview
  • 7.1.3 Pfizer Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.1.4 Pfizer Conjugate Vaccine Product Offerings
  • 7.1.5 Pfizer Recent Development
• 7.2 GSK
  • 7.2.1 GSK Company Information
  • 7.2.2 GSK Introduction and Business Overview
  • 7.2.3 GSK Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.2.4 GSK Conjugate Vaccine Product Offerings
  • 7.2.5 GSK Recent Development
• 7.3 Sanofi
  • 7.3.1 Sanofi Company Information
  • 7.3.2 Sanofi Introduction and Business Overview
  • 7.3.3 Sanofi Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.3.4 Sanofi Conjugate Vaccine Product Offerings
  • 7.3.5 Sanofi Recent Development
• 7.4 Merck
  • 7.4.1 Merck Company Information
  • 7.4.2 Merck Introduction and Business Overview
  • 7.4.3 Merck Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.4.4 Merck Conjugate Vaccine Product Offerings
  • 7.4.5 Merck Recent Development
• 7.5 Walvax Biotechnology
  • 7.5.1 Walvax Biotechnology Company Information
  • 7.5.2 Walvax Biotechnology Introduction and Business Overview
  • 7.5.3 Walvax Biotechnology Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.5.4 Walvax Biotechnology Conjugate Vaccine Product Offerings
  • 7.5.5 Walvax Biotechnology Recent Development
• 7.6 Royal (Wuxi) Bio-Pharmaceutical
  • 7.6.1 Royal (Wuxi) Bio-Pharmaceutical Company Information
  • 7.6.2 Royal (Wuxi) Bio-Pharmaceutical Introduction and Business Overview
  • 7.6.3 Royal (Wuxi) Bio-Pharmaceutical Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.6.4 Royal (Wuxi) Bio-Pharmaceutical Conjugate Vaccine Product Offerings
  • 7.6.5 Royal (Wuxi) Bio-Pharmaceutical Recent Development
• 7.7 Bharat Biotech
  • 7.7.1 Bharat Biotech Company Information
  • 7.7.2 Bharat Biotech Introduction and Business Overview
  • 7.7.3 Bharat Biotech Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.7.4 Bharat Biotech Conjugate Vaccine Product Offerings
  • 7.7.5 Bharat Biotech Recent Development
• 7.8 Zhifei Biologic
  • 7.8.1 Zhifei Biologic Company Information
  • 7.8.2 Zhifei Biologic Introduction and Business Overview
  • 7.8.3 Zhifei Biologic Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.8.4 Zhifei Biologic Conjugate Vaccine Product Offerings
  • 7.8.5 Zhifei Biologic Recent Development
• 7.9 Beijing Minhai Biotechnology
  • 7.9.1 Beijing Minhai Biotechnology Company Information
  • 7.9.2 Beijing Minhai Biotechnology Introduction and Business Overview
  • 7.9.3 Beijing Minhai Biotechnology Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.9.4 Beijing Minhai Biotechnology Conjugate Vaccine Product Offerings
  • 7.9.5 Beijing Minhai Biotechnology Recent Development
• 7.10 SinoPharma
  • 7.10.1 SinoPharma Company Information
  • 7.10.2 SinoPharma Introduction and Business Overview
  • 7.10.3 SinoPharma Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.10.4 SinoPharma Conjugate Vaccine Product Offerings
  • 7.10.5 SinoPharma Recent Development

8 Industry Chain Analysis

• 8.1 Conjugate Vaccine Industrial Chain
• 8.2 Conjugate Vaccine Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Conjugate Vaccine Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Conjugate Vaccine Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer